AzTrials
AzTrials

Major Depressive DisorderPhase 2STEP-D222NCT01052077

Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder

A Phase 2 study testing OPC-34712 and ADT in people with Major Depressive Disorder, run by Otsuka Pharmaceutical Development & Commercialization, Inc. at 43 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This is a Double-blind study wherein patients with Major Depressive Disorder (MDD) will receive either from 1 to 3 mg a day of study medication (OPC-34712)or placebo (an inactive substance) in addition to an FDA approved antidepressant in order to determine if the study medication is effective as an add on treatment… Read more about this study

Who is it for?
Ages 18 to 65 years
Conditions the study is for
Major Depressive Disorder
What is being tested?
OPC-34712 and ADT
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
773 participants
Where
43 sitesUnited States
Study dates
Mar 2010to Nov 2011
Phase
Phase 2
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Male or female subjects between 18 and 65 years of age, with diagnosis of major depressive disorder, as defined by DSM-IV-TR criteria
  • The current depressive episode must be equal to or greater than 8 weeks in duration
  • Subjects must report a history for the current depressive episode of an inadequate response to at least one and no more than three adequate antidepressant treatments.

Who cannot join

  • Females who are breast-feeding and/or who have a positive pregnancy test result prior to receiving study drug.
  • Subjects who report an inadequate response to more than three adequate trials of antidepressant treatments during current depressive episode at a therapeutic dose for an adequate duration.
  • Subjects with a current Axis I (DSM-IV-TR) diagnosis of: Delirium, dementia,amnestic or other cognitive disorder Schizophrenia, schizoaffective disorder, or other psychotic disorder Bipolar I or II disorder
  • Subjects with a clinically significant current Axis II (DSM-IV-TR) diagnosis of borderline, antisocial, paranoid, schizoid, schizotypal or histrionic personality disorder.

Trial locations and contacts

43 sites in 1 country.

43 sites in 1 country

United States43 sites
  • Pacific Clinical Research Medical Group

    Arcadia, California, 91007

  • Comprehensive NeuroScience, Inc.

    Atlanta, Georgia, 30328

  • FutureSearch Trials

    Austin, Texas, 78756

  • City Line Avenue Family Practice

    Bala-Cynwyd, Pennsylvania, 19004

  • Northcoast Clinical Trials

    Beachwood, Ohio, 44122

  • Northwest Clinical Research Center

    Bellevue, Washington, 98007

  • Southwestern Research

    Beverly Hills, California, 90210

  • University of Alabama at Birmingham

    Birmingham, Alabama, 35294

  • Northbrooke Research Center

    Brown Deer, Wisconsin, 53223

  • Neurobehavioral Research, Inc.

    Cedarhurst, New York, 11515

  • Psychiatric Alliance of The Blue Ridge

    Charlottesville, Virginia, 22903

  • Center for Emotional Fitness

    Cherry Hill, New Jersey, 08002

  • Patient Priority Clinical sites, LLC

    Cincinnati, Ohio, 45242

  • CNS Clinical Research Group

    Coral Springs, Florida, 33067

  • FutureSearch Trials of Dallas

    Dallas, Texas, 75231

  • Midwest Clinical Research Center

    Dayton, Ohio, 45408

  • MSU/Institute for Health Studies

    East Lansing, Michigan, 48824

  • Gulfcoast Clinical Research Center

    Fort Myers, Florida, 33912

  • Clinical InSights

    Glen Burnie, Maryland, 21061

  • NeuroScience, Inc.

    Herndon, Virginia, 20170

  • Goldpoint Clinical Research, LLC

    Indianapolis, Indiana, 46260

  • Clinical Neuroscience Solutions, Inc.

    Jacksonville, Florida, 32216

  • Lincoln Research

    Lincoln, Rhode Island, 02865

  • Clinical NeuroScience Solutions, Inc.

    Memphis, Tennessee, 38119

  • Eastside Comprehensive Medical Center

    New York, New York, 10021

  • Medical & Behavioral Health Research, PC

    New York, New York, 10023

  • Scientific Clinical Research, Inc.

    North Miami, Florida, 33161

  • Excell Research

    Oceanside, California, 92056

  • IPS Research Company

    Oklahoma City, Oklahoma, 73103

  • Clinical Neuroscience Solutions, Inc.

    Orlando, Florida, 32806

  • Vince and Associates Clinical Research

    Overland Park, Kansas, 66212

  • University of Pennsylvania

    Philadelphia, Pennsylvania, 19104

  • Pharmasite Research, Inc.

    Pikesville, Maryland, 21208

  • Summit Research Network (Oregon), LLC

    Portland, Oregon, 97210

  • Finger Lakes Clinical Research

    Rochester, New York, 14618

  • Radiant Research

    Salt Lake City, Utah, 84107

  • Clinical Trials of Texas

    San Antonio, Texas, 78229

  • Affiliated Research Institute

    San Diego, California, 92108

  • Neuropsychiatric Research Center of Orange County

    Santa Ana, California, 92782

  • Summit Research Network (Seattle), LLC

    Seattle, Washington, 98104

  • California Neuroscience Research Medical Group, Inc.

    Sherman Oaks, California, 91403

  • Carman Research

    Smyrna, Georgia, 30080

  • Richmond Behavioral Associates

    Staten Island, New York, 10312

Other trials in United States

About this study

Official title: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of OPDC-34712 (1 to 3 mg/Day) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder.

This is a Double-blind study wherein patients with Major Depressive Disorder (MDD) will receive either from 1 to 3 mg a day of study medication (OPC-34712)or placebo (an inactive substance) in addition to an FDA approved antidepressant in order to determine if the study medication is effective as an add on treatment of MDD.

Being tested
OPC-34712, Placebo, ADT
Keywords
OPC-34712, Major Depressive Disorder, Adjunctive Treatment
Medical subject headings
Depressive Disorder, Major

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • OPC-34712Drug

    Tablets, Oral, 1 - 3 mg OPC-34712

  • PlaceboDrug

    Placebo

  • ADTDrug

    Also called FDA Approved Antidepressant (ADT)

Study groups in NCT01052077
Study groupRoleWhat they receive
Brexipiprazole + ADTExperimentalOPC-34712 Tablets, Oral, 1 - 3 mg OPC-34712 + ADT
Receives: Drug: OPC-34712; Drug: Placebo; Drug: ADT
Placebo + ADTPlacebo comparatorPlacebo + ADT
Receives: Drug: Placebo; Drug: ADT

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change From the End of Phase A (Week 8 Visit) to the End of Phase B (Week 14 Visit) in the Montgomery Asberg Depression Rating Scale (MADRS) Total Score.

    The MADRS was utilized as the primary efficacy assessment of a participants level of depression. The MADRS consisted of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS Total Score is the sum of ratings for all 10 items; therefore, possible total scores range from 0 to 60. The MADRS total score were to be unevaluable if less than 8 of the 10 items were recorded. If 8 or 9 of the 10 items were recorded, the MADRS total score was the mean of the recorded items multiplied by 10 and then rounded of to the first decimal place.

    Measured: Baseline (end of week 8) to Week 14

Secondary outcomes (9)
  1. Change From End of Phase A (Week 8) to Phase B in Sheehan Disability Scale (SDS) Score.

    The SDS was a self-rated instrument used to measure the effect of the participants symptoms on work/school, social life, and family/home responsibilities. For each of the three items, scores ranged from 0 through 10. The number most representative of how much each area was disrupted by symptoms was marked along the line from 0= not at all, to 10= extremely. Scores of 5 and above are associated with significant functional impairment. The SDS total score ranges from 0 to 30, with higher values indicating greater disruption in the participant's work/social/family life. For the work/school item, no response was to be entered if the participant did not work or go to school for reasons unrelated to the disorder and a response therefore not being applicable. The Mean SDS score were calculated over the three item scores. All three item scores were needed to be available with the exception of the work/school item score when this item was not applicable.

    Measured: Baseline (end of week 8) to Week 14

  2. Change From End of Phase A (Week 8 Visit) in MADRS Total Score for Every Trial Week Visit in Phase B.

    The MADRS was utilized as the primary efficacy assessment of a participants level of depression. The MADRS consisted of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS Total Score is the sum of ratings for all 10 items; therefore, possible total scores range from 0 to 60. The MADRS total score were to be unevaluable if less than 8 of the 10 items were recorded. If 8 or 9 of the 10 items were recorded, the MADRS total score was the mean of the recorded items multiplied by 10 and then rounded of to the first decimal place.

    Measured: Baseline (end of week 8) to Week 14

  3. Change From End of Phase A (Week 8 Visit) to Phase B by Study Week in Clinical Global Impression- Severity Illness Scale (CGI-S) Score.

    The severity of illness for each participant was rated using the CGI-S. To perform this assessment, the investigator had to answer the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices included: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.

    Measured: Baseline (end of week 8) to Week 14

  4. Change From End of Phase A (Week 8 Visit) to Phase B by Study Week in Inventory of Depressive Symptomatology (Self-Report) (IDS-SR) Total Score.

    The IDS-SR was a 30-item self-report measure, that was used to assess core diagnostic depressive symptoms as well as atypical and melancholic symptom features of major depressive disorder (MDD). For individual items, the scores range from 0 to 3. The IDS-SR are scored by summing responses to 28 of the 30 items to obtain a total score ranging from 0 to 84, higher values indicate greater disruption in the depressive symptoms.

    Measured: Baseline (end of week 8) to Week 14

  5. Change From End of Phase A (Week 8) to End of Phase B (Week 14) in the Hamilton Depression Rating Scale 17-item Version (HAM-D17) Total Score.

    The HAM-D17 was utilized as a secondary assessment of a participants level of depression. The HAM-D (17-Item) consisted of 17 items. Eight items were rated on a 0 to 2 scale (items 4, 5, 6, 12, 13, 14, 16 and 17), while nine items (items 1, 2, 3, 7, 8, 9, 10, 11, and 15) were rated on a 0 to 4 scale (twice the weight of the other items). For all of these items, 0 was the "best" rating and the highest score (2 or 4) was the "worst" rating. The possible total scores were from 0 to 52.

    Measured: Baseline (end of week 8) to Week 14

  6. Clinical Global Impression- Improvement Scale (CGI-I) Score by Study Week in Phase B Relative to End of Phase A.

    The efficacy of study medication was rated for each participant using the CGI-I. The study physician would rate the participants total improvement whether or not it is due entirely to drug treatment. Response choices included: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse.

    Measured: Baseline (end of week 8) to Week 14

  7. Number of Participants With MADRS Response During Phase B Relative to the End of Phase A (Week 8) Visit.

    A MADRS response was defined as >=50 percent reduction in MADRS Total Score from end of Phase A (Week 8 visit). The MADRS consisted of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS Total Score is the sum of ratings for all 10 items; therefore, possible total scores range from 0 to 60. The MADRS total score were to be unevaluable if less than 8 of the 10 items were recorded. If 8 or 9 of the 10 items were recorded, the MADRS total score was the mean of the recorded items multiplied by 10 and then rounded of to the first decimal place.

    Measured: Baseline (end of week 8) to Week 14

  8. Number of Participants With MADRS Remission During Phase B Relative to the End of Phase A (Week 8) Visit.

    A MADRS remission was defined as MADRS Total Score =< 10 and >= 50 percent reduction in MADRS Total Score from end of Phase A (Week 8 visit). The MADRS consisted of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS Total Score is the sum of ratings for all 10 items; therefore, possible total scores range from 0 to 60. The MADRS total score were to be unevaluable if less than 8 of the 10 items were recorded. If 8 or 9 of the 10 items were recorded, the MADRS total score was the mean of the recorded items multiplied by 10 and then rounded of to the first decimal place.

    Measured: Baseline (end of week 8) to Week 14

  9. Number of Participants With CGI-Improvement Response During Phase B Relative to the End of Phase A (Week 8).

    CGI-I Response was defined as a CGI-I score of 1 (very much improved) or 2 (much improved).

    Measured: Baseline (end of week 8) to Week 14

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 Jan 2010 (estimated)
  2. Study startMar 2010
  3. Primary completionOct 2011
  4. Study completionNov 2011

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Care provider, Investigator
Enrolment
773 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01052077
Sponsor's protocol ID
331-09-222
Acronym
STEP-D222
Status last verified
Sep 2015
First submitted
15 Jan 2010
Last updated
2 Nov 2015

Publications

  • Hobart M, Zhang P, Weiss C, Meehan SR, Eriksson H. Adjunctive Brexpiprazole and Functioning in Major Depressive Disorder: A Pooled Analysis of Six Randomized Studies Using the Sheehan Disability Scale. Int J Neuropsychopharmacol. 2019 Mar 1;22(3):173-179. doi: 10.1093/ijnp/pyy095.

    PubMed 30508090

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing OPC-34712 and ADT in people with Major Depressive Disorder, run by Otsuka Pharmaceutical Development & Commercialization, Inc. at 43 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 2 Nov 2015. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 43 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 2 Nov 2015). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change From the End of Phase A (Week 8 Visit) to the End of Phase B (Week 14 Visit) in the Montgomery Asberg Depression Rating Scale (MADRS) Total Score. (time frame: Baseline (end of week 8) to Week 14). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01052077, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Nov 2015.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in